Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people.

The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across multiple neuromuscular diseases, including ...

First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs)− The ...

In November 2025, Epicrispr Biotechnologies Inc. announced a clinical trial is to learn how safe and tolerable EPI-321 is and ...

Sara Martin, who was raised in Nahant, is currently training to run the 2026 Boston Marathon to bring awareness to the Muscular Dystrophy Association. She has raised $4,807 thus far. For Martin, the ...

For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of ...

Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...

Muscular Dystrophies are a group of genetic conditions characterized by muscle weaknesses. They are genetic conditions and have different sub-categories depending on which area of muscle mass is ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful ...

Life in the Bennett household is lively and full of love. Mariesa and Chris beam as they talk about their three sons – Aaron, ...

The powerful gene editing technology CRISPR is one small step closer to treating a human disease. In a new paper published in Science, researchers led by Eric Olson, professor and chair of molecular ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...